Transparency and freedom of information releases

A summary of the activity of the Drug Testing on Arrest (DToA) programme since its launch in March 2022.

• From: Home Office
• Updated: 11 April 2024

• Summary: Drug Testing on Arrest (DToA) programme

  This page provides a summary of the data returns from the Drug Testing on…

• Data: Drug Testing on Arrest (DToA) programme (accessible)

  These data tables were published on 3 April 2024, presenting Drug Testing…

This report sets out progress from the first year of the delivery of the drug strategy, from harm to hope.

• From: Home Office
• Updated: 27 February 2024

• From harm to hope: first annual report 2022 to 2023 (accessible)

  July 2023 Correction slip Correction Page 35, table for “Reduce…

Information about the data we collect from people in services funded by the rough sleeping drug and alcohol treatment grant.

• From: Office for Health Improvement and Disparities
• Updated: 22 July 2022

• Rough sleeping drug and alcohol treatment grant: privacy notice

  Who we are We are the Office for Health Improvement and Disparities…

Information about the data we collect as part of the license application process for doctors to prescribe diamorphine to treat opioid dependence.

• From: Office for Health Improvement and Disparities
• Updated: 22 July 2022

Why we collect data for the Individual Placement and Support for Alcohol and Drug Dependence (IPS-AD) trial, what we do with it and who we share it with.

• From: Office for Health Improvement and Disparities
• Updated: 28 January 2022

The first annual report from the UK Recovery Champion outlines the work he has undertaken since his appointment and sets out his future work programme.

• From: Home Office
• Updated: 9 December 2021

A document developed by the Advisory Council on the Misuse of Drugs (ACMD) to outline the governing process for preparing evidence-based advice.

• From: Advisory Council on the Misuse of Drugs
• Updated: 4 May 2021

This report by the Advisory Council on the Misuse of Drugs (ACMD) investigates the impact on drug treatment.

• From: Advisory Council on the Misuse of Drugs
• Updated: 6 September 2017

A review of the evidence on the 2016 drug strategy by the Advisory Council on the Misuse of Drugs (ACMD).

• From: Advisory Council on the Misuse of Drugs
• Updated: 14 July 2017

An evaluation review of the Psychoactive Substances Bill by the Advisory Council on the Misuse of Drugs (ACMD).

• From: Advisory Council on the Misuse of Drugs
• Updated: 14 July 2017

A review of the evidence of use and harm of Methiopropamine (MPA) by the Advisory Council on the Misuse of Drugs (ACMD).

• From: Advisory Council on the Misuse of Drugs
• Updated: 16 June 2017

Minutes of the Advisory Council on the Misuse of Drugs.

• From: Advisory Council on the Misuse of Drugs
• Updated: 24 October 2013

Figures on methylphenidate base and methylphenidate hydrochloride importation between 2010 and 2012 were requested.

• From: Home Office
• Updated: 19 August 2013

Information regarding various aspects of the FRANK drugs advisory service.

• From: Home Office
• Updated: 11 January 2011

This publication scheme is in accordance with the ACMD policy on openness and transparency detailed in the ACMD’s Code of Practice.

• From: Advisory Council on the Misuse of Drugs
• Updated: 6 May 2010

Agenda details for ACMD meeting on 29 march 2010

• From: Advisory Council on the Misuse of Drugs
• Updated: 26 March 2010

In the UK today, a large proportion of young people use tobacco, alcohol and other drugs in the pursuit of pleasure, solace, acceptance or escape…

• From: Advisory Council on the Misuse of Drugs
• Updated: 14 September 2006

Request for details of the background that led to David Blunkett's decision to downgrade cannabis from a class B drug to a class C drug.

• From: Home Office
• Updated: 16 February 2006